Q4-FY26 · Niraj
We are the first and the only CDMO partner for the first three generic semaglutide approvals in all the highly regulated markets US and Canada.
ONESOURCESPECIALTYPHARMA / language trends
Read confidence between the lines.
Onesource Specialty Pharma · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q4-FY26 · Arun
We decided to defer this transaction until such time both One Source delivers on its 400 million and the incoming assets deliver on its 40 million of EBIT.
Q4-FY26 · Niraj
The biggest challenge actually for the customers is access to capacity... customers have done a capacity reservation with us including take or pay kind of contract.